Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 5/20 | 0.56 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.56 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.56 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.56 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.56 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 8/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180455 | 1.00 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14364747 | 0.95 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8893248 | 0.92 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1006593 | 0.92 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8893226 | 0.88 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14389899 | 0.86 | PSMB8 (0.44) | BACE1 | |
| SCHEMBL8893631 | 0.85 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8893270 | 0.85 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9397295 | 0.83 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8893043 | 0.83 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592368-B2 | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-22 | — | — | US | claimed |
| US-20050148548-A1 | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors | VERTEX PHARMACEUTICALS INC. | 2005-07-07 | — | — | US | claimed |
| US-6838474-B2 | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2005-01-04 | — | — | US | claimed |
| US-6559137-B1 | Characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148548-A1 | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors | PRSS1, TMPRSS15, SI | PSEN1 196/4885PSEN2 399/4885APH1B 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.